These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26214403)

  • 1. N'-Alkylaminosulfonyl Analogues of 6-Fluorobenzylideneindolinones with Desirable Physicochemical Profiles and Potent Growth Inhibitory Activities on Hepatocellular Carcinoma.
    Chen X; Yang T; Deivasigamani A; Shanmugam MK; Hui KM; Sethi G; Go ML
    ChemMedChem; 2015 Sep; 10(9):1548-58. PubMed ID: 26214403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
    Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
    Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
    J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
    Jin Q; Zhang D; Gao M; Jiang C; Zhang J
    Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
    Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
    Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.
    Gao M; Yeh PY; Lu YS; Hsu CH; Chen KF; Lee WC; Feng WC; Chen CS; Kuo ML; Cheng AL
    Cancer Res; 2008 Nov; 68(22):9348-57. PubMed ID: 19010909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC).
    Xue H; Chen P; Jiao J; Zhu X
    Protein J; 2024 Aug; 43(4):793-804. PubMed ID: 38981944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
    Rezende Miranda R; Fu Y; Chen X; Perino J; Cao P; Carpten J; Chen Y; Zhang C
    J Med Chem; 2020 Oct; 63(20):11484-11497. PubMed ID: 33030342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.